Over 1 Million Americans Take Recalled Blood Pressure Drug Due to Safety Concerns

More than one million Americans are currently taking a blood pressure medication that has been recalled and upgraded to a Class II status due to serious safety concerns.

The issue involves Chlorthalidone tablets, which were first recalled on June 5 and later reclassified on June 22 because of failed dissolution specifications.

This technical failure means the drug may not dissolve correctly inside the body, potentially releasing too much or too little active ingredient within the necessary timeframe.

If the medication dissolves too slowly, patients might not absorb enough of the drug to control their symptoms effectively. Conversely, if it dissolves too quickly, dangerous side effects could occur.

Chlorthalidone is a critical prescription used to manage high blood pressure and reduce fluid retention linked to heart, liver, or kidney conditions.

Approximately 1.5 million Americans receive about five million prescriptions for this drug annually, making the potential impact of this recall widespread.

A Class II recall signifies that use of the product could cause temporary or medically reversible adverse health consequences, though serious harm is considered remote.

The specific recall covers 100-tablet and 1,000-tablet bottles of 25 mg pills with expiration dates set for April 2027.

These bottles are manufactured by Inventia Healthcare Limited and distributed by Rising Pharma Holdings, Inc., with roughly 11,460 bottles identified for removal from the market.

The affected 100-tablet bottles carry the NDC code 64980-599-01 and batch code RISA24001, while the larger 1,000-tablet bottles are marked with NDC 64980-599-10 and batch code ISB24002.

Although the FDA has not yet issued specific guidance on what patients should do, previous similar recalls have urged individuals to contact their doctors immediately.

For those relying on this drug to manage hypertension, a failure in efficacy could lead to uncontrolled high blood pressure and severe complications like stroke or heart attack.

Patients using the medication for fluid retention face risks of worsening swelling in their legs, lungs, and abdomen, which can cause shortness of breath and strain on vital organs.

Furthermore, if the drug does not work as intended, patients could suffer from electrolyte imbalances including low potassium, sodium, and magnesium levels.

These chemical disruptions can trigger muscle weakness, fatigue, cramping, irregular heartbeats, confusion, seizures, headaches, and even dangerously low blood pressure or high blood sugar.

Healthcare providers are now urging patients to monitor their symptoms closely while waiting for further instructions from regulatory authorities regarding the safety of this widely used treatment.